Clobetasol Propionato en el tratamiento de la psoriasis en placas

  1. FELIZ, Beatriz
  2. MUSICCO, Felice 1
  3. ALVAREZ, Raquel 2
  1. 1 Instituto Fisioterapéutico hospitalario IFO, Roma
  2. 2 Universidad de Salamanca
    info

    Universidad de Salamanca

    Salamanca, España

    ROR https://ror.org/02f40zc51

Journal:
Farmajournal

ISSN: 2445-1355

Year of publication: 2017

Volume: 2

Issue: 1

Pages: 111-120

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Farmajournal

Abstract

Psoriasis is a common chronic disease with significant impairment in quality of life. As there is no cure, it often requires lifelong disease control to minimize the development of skin lesions and to relieve symptoms.Psoriasis vulgaris, also called mild / moderate, is a type of psoriasis characterized by manifest localized involvement of a skin surface <10%. For this type of psoriasis, clinical studies have shown increased efficiency based on a combination treatment of topical corticosteroids class I (betamethasone dipropionate) 0.05% with salicylic acid 2-3%, unique in the market.The aim of this study was the preparation of a master formula that combines clobetasol 0.015% incorporated into salicylic vaseline 6% (for non-hirsute area) and sweet al.mond oil with salicylic acid 6% (for the hirsute area) due to the absence of a preparation to ensure the prescribed concentrations and test the effectiveness of this preparation in a sample of patients with mild / moderate psoriasis who come to the hospital through PASI and IGA indexes.

Bibliographic References

  • Akamine KL, Gustafson CJ, Yentzer BA, Edison BL, Green BA, Davis SA, et al. A double-blind, randomized clinical trial of 20% alpha/poly hydroxy acid cream to reduce scaling of lesions associated with moderate, chronic plaque psoriasis. J Drugs Dermatol. 2013; 12:855-9.
  • Dawn A, Yosipovitch G. Treating itch in psoriasis. Dermatol Nurs. 2006; 18:227-33.
  • Elie R, Durocher LP, Kavalec EC. Effect of salicylic acid on the activity of betamethasone-17,21-dipropionate in the treatment of erythematous squamous dermatoses. J Int Med Res. 1983; 11,108-112.
  • Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers and keratolytic agents in psoriasis. Clin Dermatol. 2008; 26:380-6.
  • Katz HI, Hien NT, Prawer SE, Scott JC, Grivna EM. Betamethasone dipropionate in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol. 1987; 123:1308-11.
  • Koo J, Tanner DJ, Bressinck R, Edwards L, Cornell RC, Cuffie CA, et al. Mometasone furoate 0.1 %-salicylic acid 5 % ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther. 1998; 20,283-291.
  • Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009; 61:451-85.
  • Raut AS, Prabhu RH, Patravale VB. Psoriasis clinical implications and treatment: a review. Crit Rev Ther Drug Carrier Syst. 2013; 30:183-216.
  • Van de Kerkhof PC. Consistent control of psoriasis by continuous long-term therapy: The promise of biological treatments. J Eur Acad Dermatol Venereol. 2006; 20:639-50.
  • Van de Kerkhof PC, editor. Psoriasis. St Louis, MO: Mosby; 2003.
Data source: Dialnet